Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ketil Bjarnason"'
Autor:
Yea Christopher Martyn, Marc Princivalle, Gaell Mayer, Jessica Meyer, Lucy Elliott, Pierre Broqua, Ketil Bjarnason, Richard E. White, Robert Haigh
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 320:1113-1118
Degarelix (FE 200486) is a member of a new class of water-soluble (50 mg/ml) gonadotropin-releasing hormone (GnRH) antagonists in clinical development for prostate cancer. Upon subcutaneous administration, degarelix forms a gel that results in a sust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae33bc1ef0fde9e523d88bede892c877
https://doi.org/10.1124/jpet.106.112326
https://doi.org/10.1124/jpet.106.112326
Autor:
Birte K. Skrumsager, Norma Watson, Mireille Gerrits, Benedicte Kiehr, Poul C. Pedersen, Ketil Bjarnason
Publikováno v:
British Journal of Clinical Pharmacology. 53:284-295
Aims The safety, pharmacodynamics and pharmacokinetics of levormeloxifene, a selective oestrogen receptor modulator (SERM), were investigated in postmenopausal women following single doses and multiple dosing once daily up to 56 days. Methods The two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::803ad99560937630bbf15ae75bfc203b
https://doi.org/10.1046/j.0306-5251.2001.01181.x
https://doi.org/10.1046/j.0306-5251.2001.01181.x
Publikováno v:
Maturitas. 32:161-170
Objectives : treatment with unopposed estrogen is known to increase the risk of endometrial hyperplasia, atypia, and carcinoma, and therefore the administration of a progestin during hormone replacement therapy (HRT) is recommended. The addition of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01dbf59901b7a7a340ef1593e965018f
https://doi.org/10.1016/s0378-5122(99)00033-x
https://doi.org/10.1016/s0378-5122(99)00033-x
Autor:
Birte K, Skrumsager, Benedicte, Kiehr, Poul Christian, Pedersen, Mireille, Gerrits, Norma, Watson, Ketil, Bjarnason
Publikováno v:
British journal of clinical pharmacology. 53(3)
The safety, pharmacodynamics and pharmacokinetics of levormeloxifene, a selective oestrogen receptor modulator (SERM), were investigated in postmenopausal women following single doses and multiple dosing once daily up to 56 days.The two randomized, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22efc65b616472aa24efce633be928e4
https://pubmed.ncbi.nlm.nih.gov/11874392
https://pubmed.ncbi.nlm.nih.gov/11874392
Autor:
Nina H. Bjarnason, Claus Christiansen, Ketil Bjarnason, Herjan J.T. Coelingh Bennink, Jens Haarbo
Publikováno v:
The Journal of clinical endocrinology and metabolism. 82(6)
Tibolone, a synthetic steroid with estrogenic, androgenic, and progestogenic properties relieves climacteric symptoms and prevents postmenopausal bone loss. The influence of tibolone treatment on coagulation, fibrinolysis, and lipid metabolism was in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6342583e2d676e8897d723dc219f4ad
https://pubmed.ncbi.nlm.nih.gov/9177376
https://pubmed.ncbi.nlm.nih.gov/9177376
Publikováno v:
The Journal of clinical endocrinology and metabolism. 81(7)
The aim of the study was to assess the effects of 2 yr of treatment with two dose levels of tibolone on bone mineral density and bio-chemical markers of bone metabolism in late postmenopause. Ninety-one healthy women, more than 10 yr after menopause,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2770a5a74a6adf109ce6ed0d193914c3
https://pubmed.ncbi.nlm.nih.gov/8675553
https://pubmed.ncbi.nlm.nih.gov/8675553